Indication
Alyftrek tablets are indicated for the treatment of cystic fibrosis (CF) in people aged 6 years and older who have at least one non-Class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (see sections 4.2 and 5.1).
In other countries
The same active substances on other registers, the same brand first.
National listings
The national registers that list this EU medicine.
- Alyftrek 125 MG/50 MG/10 MG Comprimidos Recubiertos con PeliculaSpain · 10,60 mg + 50 mg + 125 mgMarketed
- Alyftrek 50 MG/20 MG/4 MG Comprimidos Recubiertos con PeliculaSpain · 4,24 mg + 20 mg + 50 mgMarketed
- Alyftrek 125 mg/50 mg/10 mg filmomhulde tablettenNetherlandsAuthorised
- Alyftrek 50 mg/20 mg/4 mg filmomhulde tablettenNetherlandsAuthorised